TEE
TXG icon

Tibra Equities Europe’s 10x Genomics TXG Stock Holding History

Tibra Equities Europe’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,800
Closed -$1.35M – 249
2020
Q3 		$1.35M Buy
+10,800
New +$1.13M 0.28% 56

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Tibra Equities Europe's TXG Position: Q4 2020 in Review

Tibra Equities Europe sold out of 10x Genomics (TXG) in Q4 2020, closing a stake of 10,800 shares — an estimated $1.35M sold.

Tibra Equities Europe first reported a position in TXG in Q3 2020 and held it in 1 quarter. The position peaked at $1.35M in Q3 2020. 305 funds tracked by Wall St. Rank hold TXG as of Q4 2020.

  • Tibra Equities Europe reported no remaining 10x Genomics position as of Q4 2020 after selling out during the quarter.
  • Tibra Equities Europe sold 10,800 10x Genomics shares in Q4 2020, an estimated $1.35M.
  • Tibra Equities Europe first reported a position in 10x Genomics in Q3 2020 and held it in 1 quarter.
  • Tibra Equities Europe's 10x Genomics position peaked at $1.35M in Q3 2020.
  • 305 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2020.

Based on Tibra Equities Europe's 13F filing for Q4 2020, filed 12 Feb 2021.